Benefit risk considerations for African swine fever virus live attenuated vaccines

NPJ Vaccines. 2025 Jul 7;10(1):147. doi: 10.1038/s41541-025-01208-8.

Abstract

In response to the recent publication on safety concerns related to “ASFV-G-∆I177L” by van den Born et al. (2025), we emphasize the need for a thorough, context-specific risk assessment before drawing conclusions about the general field use of the ASFV-G-∆I177L vaccine strain. While valid safety concerns were raised, historical precedents highlight that potential risks, including reversion or recombination, can be managed effectively within structured vaccination strategies.

Publication types

  • Letter